Deep Lens (acquired by Paradigm) Alternatives & Competitors

12 companies similar to Deep Lens (acquired by Paradigm) — Accelerating clinical trial matching in oncology

Ancora.ai

Ancora.ai is a patient-first, digital clinical trial navigation tool connecting cancer pat...

9 Grant $465.00K

Zurich, Switzerland

AI Big Data +3

Massive Bio

AI-driven system connecting cancer patients to clinical trials in real time. Industrializi...

103 Series B $28.10M

Istanbul, Turkey

AI Big Data +5

Leal Health

The AI-powered patient-centric decision-support platform for patients, healthcare provider...

29 Series A $27.72M

United States

AI Health Care +2

Oatmeal Health

We deliver AI-driven cancer care and clinical trial access to transform early detection fo...

10 Pre-Seed

San Jose, United States

AI Computer Vision +3

Rival Readout

Competing with Deep Lens (acquired by Paradigm)? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout

XGC Software Inc

AI + ERP + Blockchain: Enabling Next-Generation Caregiving, Healthcare Technology, and Cli...

4 Series A

Toronto, Canada

AI Blockchain +2

HealthMatch

Connecting People To Revolutionary Drugs And Potential Cures

24 Series C $35.30M

Australia

Biotechnology Health Care +2

Virgo

Accelerate clinical trials with AI for endoscopy.

33 Venture round $9.61M

San Francisco, United Sta...

AI Computer Vision +4

Compare

Singularity.AI

Unlocking Visual Collaboration for Medical Innovation

4 Convertible Note $5.00M

Mountain View, United Sta...

AI Health Care +3

Aiforia Technologies

Translate images into data, discoveries, and diagnoses with deep learning AI for image ana...

81 IPO $65.00M

Helsinki, Finland

AI Biotechnology +5

Bayesian Health

Co-pilot for doctors and nurses — empowering clinicians with real-time care signals to man...

32 Venture round $15.23M

New York, United States

AI Health Care +1

Deep Bio Inc.

Al healthcare company with in-house expertise in deep learning and cancer pathology.

30 Series B $5.60M

Seoul, Korea South

AI Biotechnology +1

radiomics.bio

Radiomics, Deep Learning & Federated Learning for AI powered drug development trajectory a...

Liege, Belgium

AI Biotechnology +1

About Deep Lens (acquired by Paradigm)

Deep Lens, with the slogan "Accelerating clinical trial matching in oncology," is a digital healthcare company that was established in 2017 and is headquartered in the United States. The company focuses on leveraging AI, machine learning, and life sciences to expedite the recruitment of suitable cancer patients for cli...

Business keywords

Digital Healthcare, Clinical Trials, Oncology, AI-driven Platform, Cancer Patient Recruitment, Digital Pathology Workflow, AI Image Detection, Collaboration Platform, Cloud Storage, API Integration, Pathology Research, Pharmaceuticals, Cancer Research, Pathology

Frequently Asked Questions

Companies similar to Deep Lens (acquired by Paradigm) include Ancora.ai, Massive Bio, Leal Health, Oatmeal Health, XGC Software Inc. They work in AI and Health Care and share Deep Lens (acquired by Paradigm)'s focus on oncology, clinical trials and pharmaceuticals.

Bounce Watch lists 12 companies that share Deep Lens (acquired by Paradigm)'s industries and are closest to it in business tags, services, target customers, business model and size.

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Deep Lens (acquired by Paradigm): 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Book a 7-day Readout Get a free snapshot

Explore Related

Deep Lens (acquired by Paradigm) Profile Ancora.ai Alternatives Massive Bio Alternatives Leal Health Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Deep Lens (acquired by Paradigm) on 11 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 8 Nov 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.